Polycythemia Vera Drug Market: A Study of Besremi, Jakafi, and Rusfertide
Polycythemia Vera Treatment Landscape FDA-approved medication Jakafi (ruxolitinib), created by Incyte, is used to treat Polycythemia Vera . Jakafi is a JAK1/JAK2 inhibitor that lessens the overactive JAK1 and JAK2 signalling that is connected to the symptoms of polycythemia vera . The patent for Jakafi expires in 2027, but numerous businesses have already submitted generic applications. The introduction of generics could be delayed, though, as a result of legal disputes. PharmaEssentia’s new entrant, entry into NCCN guidelines, insights on pricing, and launches PharmaEssentia's Besremi (Ropeginterferon alfa-2b) is a brand-new medication for Polycythemia Vera. It works differently than Jakafi and is administered subcutaneously. Besremi is an interferon alpha-2b derivative that controls the immune system and bone marrow, which can aid in reducing Polycythemia Vera's excessive production of blood cells. Besremi obtained FDA approval in the US in 2021 after being approved in the ...